Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
220.36
-0.14 (-0.06%)
At close: Dec 5, 2025, 4:00 PM EST
219.64
-0.72 (-0.33%)
After-hours: Dec 5, 2025, 7:16 PM EST
Cidara Therapeutics Revenue
In the year 2024, Cidara Therapeutics had annual revenue of $1.28M, down -94.52%.
Revenue (ttm)
$1.28M
Revenue Growth
-94.52%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
6.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.28M | -22.01M | -94.52% |
| Dec 31, 2023 | 23.28M | -213.00K | -0.91% |
| Dec 31, 2022 | 23.50M | -26.08M | -52.60% |
| Dec 31, 2021 | 49.57M | 37.51M | 310.81% |
| Dec 31, 2020 | 12.07M | -8.85M | -42.30% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CDTX News
- 11 days ago - Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations - GlobeNewsWire
- 15 days ago - Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer - The Motley Fool
- 15 days ago - Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. - The Motley Fool
- 16 days ago - Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025 - Forbes
- 18 days ago - This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover - The Motley Fool
- 18 days ago - Merck expects over $5 billion commercial opportunity from Cidara's flu drug - Reuters
- 18 days ago - Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
- 19 days ago - Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX - Business Wire